March 03, 2026 (MLN): The Board of Directors of Citi Pharma Limited has approved the initiation of the Initial Public Offering of Citi Pharma's wholly owned subsidiary, Citi Veterinary Pharma Limited.

The Company has been established as a dedicated entity focused towards the manufacturing of Veterinary focused API's and Pharmaceutical products for the consumption of the local market, the on PSX revealed today.

In this regard, the Board has approved the appointment of K-Trade Securities Limited as the Consultant to Issue with the aim to list the Company at the earliest. The Company plans to raise between Rs1.0bn to Rs2.0bn through the IPO.

This marks a significant milestone for Citi Pharma Limited for increasing it's revenue sources through diversification in a pharma related field. It may also be informed that Citi Pharma plans to generate approx. Rs1.50bn in revenue through trading of veterinary products in FY26.

Copyright